Cellectis SA (CLLS) Shares Up 2.8%
Cellectis SA (NASDAQ:CLLS) shot up 2.8% on Wednesday . The company traded as high as $27.00 and last traded at $26.12, with a volume of 92,832 shares changing hands. The stock had previously closed at $25.41.
CLLS has been the subject of several recent research reports. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Cellectis SA in a report on Tuesday, May 31st. Piper Jaffray Cos. restated a “buy” rating on shares of Cellectis SA in a report on Sunday, May 8th. Zacks Investment Research lowered shares of Cellectis SA from a “hold” rating to a “sell” rating in a report on Thursday, May 12th. Finally, Ladenburg Thalmann initiated coverage on shares of Cellectis SA in a report on Tuesday, April 5th. They issued a “buy” rating and a $45.00 price target for the company. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Cellectis SA has a consensus rating of “Buy” and a consensus target price of $44.67.
The stock’s market cap is $910.64 million. The stock has a 50-day moving average price of $28.87 and a 200 day moving average price of $26.85.
Cellectis SA (NASDAQ:CLLS) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.18. On average, analysts forecast that Cellectis SA will post ($2.07) earnings per share for the current year.
An institutional investor recently raised its position in Cellectis SA stock. Tekla Capital Management LLC raised its stake in Cellectis SA (NASDAQ:CLLS) by 30.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 207,250 shares of the company’s stock after buying an additional 48,868 shares during the period. Tekla Capital Management LLC owned approximately 0.59% of Cellectis SA worth $6,431,000 as of its most recent SEC filing.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.